Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Fusion Pharmaceuticals reports Q3 EPS (45c), consensus (60c) » 07:31
11/09/21
11/09
07:31
11/09/21
07:31
FUSN

Fusion Pharmaceuticals

$6.92 /

-0.01 (-0.14%)

As of September 30 Fusion…

As of September 30 Fusion held cash, cash equivalents and investments of $238.2M, compared to cash, cash equivalents and investments of $299.5M as of December 31, 2020. Fusion expects its cash, cash equivalents and investments as of September 30, 2021 will enable the Company to fund its operations through the end of 2023. CEO John Valliant, commented, "Despite our efforts to mitigate the impacts of the COVID-19 pandemic, including the addition of new trial sites in multiple geographic regions, we have seen patient enrollment rates decline largely due to resourcing and reduced staffing issues at trial sites. Longer timelines to enroll patients have persisted and therefore we are shifting our expectation for multi-dose data to the second half of 2022. We continue to make patient recruitment a top priority, are working closely with our trial sites to support their efforts and believe that with increased vaccination rates recruitment will return to previous levels."

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$6.92 /

-0.01 (-0.14%)

FUSN Fusion Pharmaceuticals
$6.92 /

-0.01 (-0.14%)

10/19/21 Morgan Stanley
Fusion Pharmaceuticals assumed with an Overweight at Morgan Stanley
08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
FUSN Fusion Pharmaceuticals
$6.92 /

-0.01 (-0.14%)

FUSN Fusion Pharmaceuticals
$6.92 /

-0.01 (-0.14%)

Hot Stocks
Fusion Pharmaceuticals names Christopher Leamon as Chief Scientific Officer » 16:55
11/02/21
11/02
16:55
11/02/21
16:55
FUSN

Fusion Pharmaceuticals

$7.00 /

+0.02 (+0.29%)

, NVS

Novartis

$83.77 /

-0.29 (-0.34%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals (FUSN) announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. Dr. Leamon was most recently executive director, radioligand drug discovery at Novartis (NVS).

ShowHide Related Items >><<
NVS Novartis
$83.77 /

-0.29 (-0.34%)

FUSN Fusion Pharmaceuticals
$7.00 /

+0.02 (+0.29%)

FUSN Fusion Pharmaceuticals
$7.00 /

+0.02 (+0.29%)

10/19/21 Morgan Stanley
Fusion Pharmaceuticals assumed with an Overweight at Morgan Stanley
08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
NVS Novartis
$83.77 /

-0.29 (-0.34%)

10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
NVS Novartis
$83.77 /

-0.29 (-0.34%)

FUSN Fusion Pharmaceuticals
$7.00 /

+0.02 (+0.29%)

NVS Novartis
$83.77 /

-0.29 (-0.34%)

NVS Novartis
$83.77 /

-0.29 (-0.34%)

FUSN Fusion Pharmaceuticals
$7.00 /

+0.02 (+0.29%)

NVS Novartis
$83.77 /

-0.29 (-0.34%)

Over a month ago
Hot Stocks
Fusion Pharma's targeted Alpha therapies demonstrate therapeutic efficacy » 16:26
10/20/21
10/20
16:26
10/20/21
16:26
FUSN

Fusion Pharmaceuticals

$7.59 /

+0.09 (+1.20%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1. Outcomes demonstrated that FPI-1966 when administered with vofatamab results in high tumor delivery and low off-target uptake. Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model. Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1, were presented in an oral presentation.Results demonstrate superior efficacy with FPI-2059 in a mouse xenograft model of colorectal cancer.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$7.59 /

+0.09 (+1.20%)

FUSN Fusion Pharmaceuticals
$7.59 /

+0.09 (+1.20%)

10/19/21 Morgan Stanley
Fusion Pharmaceuticals assumed with an Overweight at Morgan Stanley
08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
FUSN Fusion Pharmaceuticals
$7.59 /

+0.09 (+1.20%)

FUSN Fusion Pharmaceuticals
$7.59 /

+0.09 (+1.20%)

Initiation
Fusion Pharmaceuticals assumed with an Overweight at Morgan Stanley » 08:35
10/19/21
10/19
08:35
10/19/21
08:35
FUSN

Fusion Pharmaceuticals

$7.28 /

-0.22 (-2.93%)

Morgan Stanley analyst…

Morgan Stanley analyst Michael Ulz assumed coverage of Fusion Pharmaceuticals with an Overweight rating and $19 price target. He believes Fusion's next generation TAT platform offers potential advantages over existing radiopharmaceuticals to treat cancer and views the company's broad manufacturing capabilities giving it "key advantages in the field," Ulz said.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$7.28 /

-0.22 (-2.93%)

FUSN Fusion Pharmaceuticals
$7.28 /

-0.22 (-2.93%)

08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
FUSN Fusion Pharmaceuticals
$7.28 /

-0.22 (-2.93%)

FUSN Fusion Pharmaceuticals
$7.28 /

-0.22 (-2.93%)

Hot Stocks
Fusion Pharmaceuticals names Mohit Rawat as President and Chief Business Officer » 16:06
09/28/21
09/28
16:06
09/28/21
16:06
FUSN

Fusion Pharmaceuticals

$8.11 /

-0.19 (-2.29%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals announced the appointment of Mohit Rawat as President and Chief Business Officer. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.11 /

-0.19 (-2.29%)

FUSN Fusion Pharmaceuticals
$8.11 /

-0.19 (-2.29%)

08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
FUSN Fusion Pharmaceuticals
$8.11 /

-0.19 (-2.29%)

FUSN Fusion Pharmaceuticals
$8.11 /

-0.19 (-2.29%)

Over a quarter ago
Initiation
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside » 07:44
08/26/21
08/26
07:44
08/26/21
07:44
FUSN

Fusion Pharmaceuticals

$8.23 /

-0.08 (-0.96%)

B. Riley analyst Justin…

B. Riley analyst Justin Walsh initiated coverage of Fusion Pharmaceuticals with a Buy rating and $17 price target, which represents 108% potential upside from current levels. Fusion is a clinical-stage oncology company developing next-generation targeted radiopharmaceuticals that make use of alpha-emitting radioisotope actinium-225, Walsh tells investors in a research note. The analyst believes Fusion is "poised to take advantage of the current buzz around radiopharmaceuticals and cement itself as a leader in the field."

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

Initiation
Fusion Pharmaceuticals initiated with a Buy at B. Riley » 04:41
08/26/21
08/26
04:41
08/26/21
04:41
FUSN

Fusion Pharmaceuticals

$8.23 /

-0.08 (-0.96%)

B. Riley initiated…

B. Riley initiated coverage of Fusion Pharmaceuticals with a Buy rating and $17 price target.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

FUSN Fusion Pharmaceuticals
$8.23 /

-0.08 (-0.96%)

Hot Stocks
Fusion Pharmaceuticals and Triumf expand R&D collaboration for actinium » 16:25
08/12/21
08/12
16:25
08/12/21
16:25
FUSN

Fusion Pharmaceuticals

$8.10 /

+0.03 (+0.37%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals and TRIUMF, Canada's particle accelerator centre, have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope. In December 2020, Fusion and TRIUMF entered a collaboration and supply agreement to develop, produce and procure the supply of actinium-225 to Fusion. As part of this agreement, Fusion will continue its investment of up to C$25M in TRIUMF to advance technology and processes for actinium-225 production.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.10 /

+0.03 (+0.37%)

FUSN Fusion Pharmaceuticals
$8.10 /

+0.03 (+0.37%)

FUSN Fusion Pharmaceuticals
$8.10 /

+0.03 (+0.37%)

Earnings
Fusion Pharmaceuticals reports Q2 EPS (63) wit items, consensus (39c) » 07:33
08/10/21
08/10
07:33
08/10/21
07:33
FUSN

Fusion Pharmaceuticals

$8.14 /

+0.03 (+0.37%)

Reports Q2 revenue…

Reports Q2 revenue $521,000, consensus $0. Q2 EPS includes a change in fair value of preferred share tranche right liability and warrant liability. As of June 30 Fusion held cash, cash equivalents and investments of $260.5M, compared to cash, cash equivalents and investments of $299.5M as of December 31, 2020. Fusion expects its cash, cash equivalents and investments as of June 30, 2021 will enable the Company to fund its operations through the end of 2023. "We are building a fully integrated radiopharmaceutical company based upon our platform, reflecting a diverse pipeline of targeted alpha therapies in development supported by manufacturing and supply chain expertise," said CEO John Valliant. "We expect to have three clinical programs employing differentiated radiopharmaceuticals underway by mid-next year. In addition to our ongoing Phase 1 study of FPI-1434, the investigational new drug application of FPI-1966 was recently cleared by the FDA, and we intend to submit an IND application for FPI-2059 in the first half of 2022. In parallel, we are quickly advancing programs under our partnership agreement with AstraZeneca and are planning for a combination study of FPI-1434 with KEYTRUDA."

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.14 /

+0.03 (+0.37%)

FUSN Fusion Pharmaceuticals
$8.14 /

+0.03 (+0.37%)

FUSN Fusion Pharmaceuticals
$8.14 /

+0.03 (+0.37%)

Hot Stocks
Fusion Pharmaceuticals says FDA clears IND for FPI-1966 » 16:59
07/28/21
07/28
16:59
07/28/21
16:59
FUSN

Fusion Pharmaceuticals

$8.17 /

+0.14 (+1.74%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals announced that the U.S. FDA has cleared the company's Investigational New Drug applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967 (FPI-1967). FPI-1966 is a targeted alpha therapy designed to use vofatamab, a human monoclonal antibody, to target and deliver actinium-225 to tumor sites expressing fibroblast growth factor 3, a protein that is overexpressed in multiple tumor types, particularly head and neck and bladder cancers. FPI-1966 utilizes Fusion's Fast-Clear linker to connect vofatamab to actinium-225.

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$8.17 /

+0.14 (+1.74%)

FUSN Fusion Pharmaceuticals
$8.17 /

+0.14 (+1.74%)

FUSN Fusion Pharmaceuticals
$8.17 /

+0.14 (+1.74%)

FUSN Fusion Pharmaceuticals
$8.17 /

+0.14 (+1.74%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.